Benefit-Risk Appraisal of Medicines: A systematic approach to decision-making / Edition 1

Hardcover (Print)
Used and New from Other Sellers
Used and New from Other Sellers
from $83.99
Usually ships in 1-2 business days
(Save 32%)
Other sellers (Hardcover)
  • All (6) from $83.99   
  • New (4) from $93.86   
  • Used (2) from $83.99   

Overview

Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available.

The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes and leads to an overall appraisal of benefits and risks of medicines.

Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors’ new model and analyses the implications of its implementation.

  • Describes an innovative, systematic model which leads to transparent and responsible benefit-risk decision making
  • Contributes important ideas to the debate on benefit-risk appraisal
  • Provides a future framework for benefit-risk appraisal of medicines

Benefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities,, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology.

Read More Show Less

Product Details

  • ISBN-13: 9780470060858
  • Publisher: Wiley
  • Publication date: 11/16/2009
  • Edition number: 1
  • Pages: 294
  • Sales rank: 1,240,472
  • Product dimensions: 6.80 (w) x 9.80 (h) x 0.90 (d)

Table of Contents

Foreword vii

Preface ix

1 Concept and Scope of Benefit-Risk Evaluation of Medicines 1

1.1 Historical background 1

1.2 The regulatory systems for assessing medicines 3

1.3 Benefit-risk assessment: definitions 4

1.4 Views and perceptions of benefits and risks of medicines 6

1.5 Stages and concepts in benefit-risk assessment 11

1.6 Benefit-risk assessment: the current regulatory environment 19

1.7 Benefit-risk assessment in other disciplines 19

1.8 Specific methods and models for benefit-risk assessment 21

1.9 Discussions with stakeholders on the concepts and models for benefit-risk evaluation 30

2 Criteria for a Benefit-Risk Model: a Conceptual Framework 31

2.1 Introduction 31

2.2 Regulatory guidelines on benefit and risk criteria 32

2.3 Identification, definition and rationale of relevant benefit and risk criteria 35

2.4 Verification of the list of benefit and risk criteria by means of a survey 59

3 Review of the Current Benefit-Risk Assessment Models 63

3.1 Background 63

3.2 Evaluation of the existing benefit-risk assessment models 65

3.3 Review of models in single clinical trials and for specific medicines 86

3.4 Conclusion 93

3.5 Newer models 96

4 Defining a Systematic Approach to Decision Making 99

4.1 Introduction 99

4.2 Objectives and features of the ideal model for benefit-risk assessment 100

4.3 The use of decision-analysis techniques for the development of the new model 101

5 Development and Application of a Benefit-Risk Assessment Model Based on Multi-Criteria Decision Analysis 111

5.1 Introduction 111

5.2 Conceptualization of the new model 111

5.3 Reasons for using decision analysis techniques in the new model 113

5.4 The use of MCDA in the new model 114

5.5 Development of the new model 116

5.6 Applicability of the new model 133

5.7 Summary 148

5.8 Review of the MCDA model 149

6 A Future Framework for Benefit-Risk Appraisal of Medicines 151

6.1 Background 151

6.2 Development of a benefit-risk framework for regulatory review of new medicines 151

6.3 Prerequisites of a benefit-risk framework for the registration of a new medicine 161

6.4 Current status of benefit-risk assessment among companies and agencies 164

6.5 Constructing a benefit-risk framework 172

6.6 Conclusion 184

Appendices

Appendix 1 Summary Reports of the CMR International Institute for Regulatory Science March 2004 and June 2005 Workshops on Benefit-Risk 185

Appendix 2 Office of Health Economics Briefing: Challenges and Opportunities for Improving Benefit-risk Assessment of Pharmaceuticals from an Economic Perspective - James Cross and Louis Garrison (August 2008) 207

Appendix 3 Reflection Paper on Benefit-risk Assessment Methods in the Context of the Evaluation of Marketing Authorisation Applications of Medicinal Products for Human Use - Committee for Medicinal Products for Human Use (March 2008) 233

Appendix 4 Commentaries on 'A Quantitative Approach to Benefit-risk Assessment of Medicines' Pharmacoepidemiology and Drug Safety, 2007, 16 251

Appendix 5 Forum on Benefit: Risk Decision Analysis - Summary of Discussions and Recommendations - MHRA (September 2008) 261

References 271

Index 285

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)